Susceptibility of Cryptococcus neoformans and Cryptococcus gattii from clinical and environment sources in Nairobi, Kenya

摘要: Objective : To determine anti-fungal susceptibility of Cryptococcus neoformans and gattii from environmental clinical sources in Nairobi, Kenya. Design Prospective study. Setting Kenya Medical Research Institute, Mycology laboratory, Subjects A total 123 isolates were tested for their to fluconazole (FLC), amphotericin B(AMP) fluorocytosine (5FC). Clinical 70(66 4 ) while 53(41 C. 12 ). The characterised using various phenotypic tests including microscopic morphology, physiological biochemical (API 20 Caux), pigmentation on bird seed agar reaction canavanineglycine- bromthymolblue agar. European Committee Anti-microbial Susceptibility Standards (EUCAST) was used as the reference method testing. Results Most isolates; (61/66; 92.4%) (38/41; 92.7%) susceptible FLC. number inhibited at dose dependent (SDD) range (16-32μg/ml) by FLC (4/66; 6.1%) (2/41; 4.9%). One isolate each; (1/66; 1.5%) (1/41; 2.4%) resistant All gatti fully percentage that (S) (MIC ≤ 1.0 μg/ml) AMP were; clinical(52/66; 90.2%) (37/41; 78.8%) rest with MIC (2-8μg/ml). Reduced susceptibilities 5FC displayed all gatii instance resistance reported ; (8/66; 12.1%) 2.4 %). Among there also decreased Minimum Inhibition Concentration (MIC) between 0.5-32 μg/ml. There no significant differences ranges among isolates. Conclusion This study demonstrated reduced commonly drugs.